Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1297885/000110465905037838/a05-13539_110q.htm
November 2005
November 2005
November 2005
November 2005
November 2005
November 2005
October 2005
October 2005
September 2005
August 2005
Exhibit 99.1
Investor Contact: Stewart A. Fisher |
Media Contact Information: Nanette Pietroforte |
EVP and CFO |
FischerHealth, Inc. |
(610) 409-2225 |
(310) 577-7870, ext. 161 |
stewart.fisher@accellent.com |
npietroforte@fischerhealth.com |
For Immediate Release
Accellent Corp. Announces Second Quarter Financial Results
Newton, MA. (August 1, 2005) Accellent Corp., formerly Medical Device Manufacturing, Inc. (the Company), a wholly owned subsidiary of Accellent Inc., announced strong results for the three months and six months ended June 30, 2005, reflecting contributions from its acquisition of MedSource Technologies, Inc. on June 30, 2004 and continued strong organic growth.
Second Quarter Financial Results
Net sales for the second quarter of 2005 increased 90% to $114.7 million compared with $60.3 million in the corresponding period of 2004. The acquisition of MedSource increased net sales by $43.9 million in the second quarter of 2005. Net income for the second quarter of 2005 was $5.9 million compared to net loss in the corresponding period of 2004 of $4.4 million. Adjusted EBITDA (1) for the second quarter of 2005 was $25.0 million compared to $11.0 million in the corresponding period of 2004. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in the financial statements accompanying this press release.
Six Months Financial Results
Net sales for the six months ended June 30, 2005 increased 99% to $223.6 million compared with $112.1 million in the corresponding period of 2004. The acquisition of MedSource increased net sales by $89.8 million for the six months ended June 30, 2005. Net income for the six months ended June 30, 2005 was $9.1 million compared to net loss in the corresponding period of 2004 of $2.0 million. Adjusted EBITDA for the six months ended June 30, 2005 was $45.0 million compared to $20.5 million in the corresponding period of 2004.
Pro Forma Financial Results (2)
Second Quarter Pro Forma Financial Results
Net sales for the second quarter of 2005 increased 6% to $114.7 million compared with pro forma net sales of $108.3 million in the corresponding period of 2004, reflecting growth in the Companys targeted cardiovascular, endoscopic and orthopaedic markets. The impact of the Companys facility rationalization program, which included the closing
1
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1297885/000110465905037838/a05-13539_110q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Accellent Corp..
Accellent Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:
CIK: 1297885
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-05-037838
Submitted to the SEC: Tue Aug 09 2005 3:25:53 PM EST
Accepted by the SEC: Tue Aug 09 2005
Period: Thursday, June 30, 2005
Industry: Surgical And Medical Instruments And Apparatus